$CLPT
ClearPoint Neuro, Inc.

2024 Q4 Form 10-Q Financial Statement

#000128555024000121 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $8.122M
YoY Change 40.96%
Cost Of Revenue $3.275M
YoY Change 31.58%
Gross Profit $4.847M
YoY Change 48.09%
Gross Profit Margin 59.68%
Selling, General & Admin $3.155M
YoY Change 8.79%
% of Gross Profit 65.09%
Research & Development $3.315M
YoY Change 36.48%
% of Gross Profit 68.39%
Depreciation & Amortization $264.0K
YoY Change 76.0%
% of Gross Profit 5.45%
Operating Expenses $6.470M
YoY Change 21.41%
Operating Profit -$5.172M
YoY Change 5.62%
Interest Expense $209.0K
YoY Change 109.0%
% of Operating Profit
Other Income/Expense, Net -$11.00K
YoY Change -8.33%
Pretax Income -$4.974M
YoY Change 3.41%
Income Tax
% Of Pretax Income
Net Earnings -$4.974M
YoY Change 3.43%
Net Earnings / Revenue -61.24%
Basic Earnings Per Share -$0.18
Diluted Earnings Per Share -$0.18
COMMON SHARES
Basic Shares Outstanding 27.58M shares 27.60M shares
Diluted Shares Outstanding 27.59M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.57M
YoY Change -11.37%
Cash & Equivalents $21.60M
Short-Term Investments
Other Short-Term Assets $1.823M
YoY Change 16.86%
Inventory $7.059M
Prepaid Expenses
Receivables $3.875M
Other Receivables $0.00
Total Short-Term Assets $34.33M
YoY Change -7.99%
LONG-TERM ASSETS
Property, Plant & Equipment $1.695M
YoY Change 25.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $148.0K
YoY Change 35.78%
Total Long-Term Assets $5.863M
YoY Change -10.17%
TOTAL ASSETS
Total Short-Term Assets $34.33M
Total Long-Term Assets $5.863M
Total Assets $40.19M
YoY Change -8.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $955.0K
YoY Change 21.04%
Accrued Expenses $5.347M
YoY Change 47.3%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.554M
YoY Change 35.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities $3.638M
YoY Change -13.79%
Total Long-Term Liabilities $3.638M
YoY Change -74.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.554M
Total Long-Term Liabilities $3.638M
Total Liabilities $11.19M
YoY Change -43.31%
SHAREHOLDERS EQUITY
Retained Earnings -$186.0M
YoY Change 10.85%
Common Stock $215.0M
YoY Change 12.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $29.00M
YoY Change
Total Liabilities & Shareholders Equity $40.19M
YoY Change -8.31%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$4.974M
YoY Change 3.43%
Depreciation, Depletion And Amortization $264.0K
YoY Change 76.0%
Cash From Operating Activities -$1.199M
YoY Change -33.02%
INVESTING ACTIVITIES
Capital Expenditures $12.00K
YoY Change -94.78%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$12.00K
YoY Change -94.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.06M
YoY Change 11078.89%
NET CHANGE
Cash From Operating Activities -1.199M
Cash From Investing Activities -12.00K
Cash From Financing Activities -10.06M
Net Change In Cash -11.27M
YoY Change 434.22%
FREE CASH FLOW
Cash From Operating Activities -$1.199M
Capital Expenditures $12.00K
Free Cash Flow -$1.211M
YoY Change -40.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001285550
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Address Address Line1
EntityAddressAddressLine1
120 S. Sierra Ave.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Solana Beach
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92075
dei City Area Code
CityAreaCode
(888)
dei Local Phone Number
LocalPhoneNumber
287-9109
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
dei Trading Symbol
TradingSymbol
CLPT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21573000 usd
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24630181 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24630181 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5609000 usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
58-2394628
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27584699 shares
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23140000 usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24599191 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24599191 shares
dei Entity Registrant Name
EntityRegistrantName
ClearPoint Neuro, Inc.
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3211000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
7059000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
7911000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1823000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1910000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
34330000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
36172000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1695000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1389000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3210000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3564000 usd
CY2024Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
198000 usd
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
386000 usd
CY2024Q3 us-gaap Indefinite Lived Contractual Rights
IndefiniteLivedContractualRights
612000 usd
CY2023Q4 us-gaap Indefinite Lived Contractual Rights
IndefiniteLivedContractualRights
1041000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
148000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
109000 usd
CY2024Q3 us-gaap Assets
Assets
40193000 usd
CY2023Q4 us-gaap Assets
Assets
42661000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
955000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
393000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3635000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2947000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1176000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1053000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
536000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
424000 usd
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1252000 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2613000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
36887000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1307000 usd
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
5000 usd
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3875000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7554000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7430000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3158000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3568000 usd
CY2024Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
480000 usd
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
541000 usd
CY2024Q3 us-gaap Secured Long Term Debt
SecuredLongTermDebt
0 usd
CY2023Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
9949000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
11192000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
21488000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27588819 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27588819 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24652729 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24652729 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
276000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
247000 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
214709000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
193382000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-185984000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-172456000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
29001000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
21173000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40193000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42661000 usd
CY2024Q3 us-gaap Revenues
Revenues
8122000 usd
CY2023Q3 us-gaap Revenues
Revenues
5762000 usd
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
3275000 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
2489000 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
4847000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
3273000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3315000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2429000 usd
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3549000 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2841000 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3155000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2900000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5172000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4897000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12000 usd
CY2024Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
209000 usd
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
100000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-4974000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4809000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27591623 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27591623 shares
us-gaap Revenues
Revenues
23619000 usd
us-gaap Revenues
Revenues
17145000 usd
us-gaap Cost Of Revenue
CostOfRevenue
9259000 usd
us-gaap Cost Of Revenue
CostOfRevenue
7544000 usd
us-gaap Gross Profit
GrossProfit
14360000 usd
us-gaap Gross Profit
GrossProfit
9601000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9060000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9057000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10673000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9248000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8769000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9036000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-14142000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-17740000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-32000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-25000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
646000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
295000 usd
us-gaap Net Income Loss
NetIncomeLoss
-13528000 usd
us-gaap Net Income Loss
NetIncomeLoss
-17470000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26840119 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26840119 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
21173000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16183000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1504000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000 usd
CY2024Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
151000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-4146000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
34584000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1796000 usd
CY2024Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
128000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
288000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-4408000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
32132000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1904000 usd
CY2024Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
61000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-4974000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
29001000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
32580000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1645000 usd
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
77000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
314000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7052000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
27410000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1584000 usd
CY2023Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
91000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4809000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
24094000 usd
us-gaap Net Income Loss
NetIncomeLoss
-13528000 usd
us-gaap Net Income Loss
NetIncomeLoss
-17470000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-507000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
903000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
740000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
443000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5204000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4536000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
51000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
42000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
692000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
590000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
126000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
157000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
662000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-434000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-263000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-88000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-241000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
40000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-22000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1373000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1023000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-635000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-553000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1422000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
243000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7707000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12551000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
696000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
167000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
0 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
10000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9137000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16183000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
10000000 usd
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
21000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
340000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
173000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
288000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
314000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6152000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
141000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1567000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3273000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23140000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27615000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21573000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24342000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Interest Paid Net
InterestPaidNet
480000 usd
us-gaap Interest Paid Net
InterestPaidNet
554000 usd
clpt Net Transfers Of Reusable Components From Loaned Systems
NetTransfersOfReusableComponentsFromLoanedSystems
400000 usd
clpt Net Transfers Of Reusable Components From Loaned Systems
NetTransfersOfReusableComponentsFromLoanedSystems
100000 usd
CY2023Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2500000 usd
CY2024Q3 clpt Number Of Customers
NumberOfCustomers
50 customer
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-186000000.0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7700000 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13700000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration Risks and Other Risks and Uncertainties</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company may at times invest its excess cash in interest bearing accounts and U.S. government debt securities. It classifies all highly liquid investments with original stated maturities of three months or less from the date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months but less than twelve months as short-term investments. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds the remainder of its cash and cash equivalents on deposit with financial institutions in the U.S. insured by the Federal Deposit Insurance Corporation. At September 30, 2024, the Company had approximately $1.1 million in bank balances that were in excess of the insured limits. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2024, there was one customer whose accounts receivable balance represented 11% of accounts receivable at that date. At December 31, 2023, there were four customers whose accounts receivable balances represented 80% of accounts receivable at that date.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One pharmaceutical customer, a related party who is a stockholder and whose chief executive officer is a member of the Company's Board of Directors, for whom the Company provides hardware, software, clinical services and market development services in support of the customer's clinical trials, and from whom the Company earns a quarterly fee, accounted for 9% and 12% of total sales in both the three and nine-month periods ended September 30, 2024 and 2023, respectively. There was one additional customer, who comprised 13% of the total sales in the three-month period ended September 30, 2024, and another customer who comprised 10% of the total sales in the three-month period ended September 30, 2023.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to granting credit to a customer, the Company generally performs credit evaluations of the customer's financial condition. In general, the Company does not require collateral from customers in connection with an extension of credit. The accounts receivable balance is reduced by an allowance for credit losses from the potential inability of the Company's customers to make required payments. The allowance for credit losses at September 30, 2024, and December 31, 2023, was $0.9 million and $1.4 million, respectively. The Company evaluates the historic loss experience on the accounts receivable balance and also considers separately customers with receivable balances that may be negatively impacted by current economic developments and market conditions. The estimate is a result of the Company's ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to emerging companies in the medical device industry, including, but not limited to: new technological innovations; acceptance and competitiveness of its products; dependence on key personnel; dependence on key suppliers; its ability to maintain its third-party collaboration, license and joint development partners, and enter into new relationships; changes in general economic conditions and interest rates; its </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to obtain additional funding to support its business; regulatory uncertainty; protection of proprietary technology; compliance with changing government regulations; uncertainty of widespread market acceptance of products; access to credit for capital purchases by customers; and intellectual property and product liability claims. Certain components used in manufacturing have relatively few alternative sources of supply and establishing additional or replacement suppliers for such components cannot be accomplished quickly. The inability of any of these suppliers to fulfill the Company’s supply requirements may negatively impact future operating results.</span></div>
CY2024Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1100000 usd
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
900000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1400000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8122000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5762000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
23619000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17145000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3875000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3211000 usd
CY2024Q3 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
662000 usd
CY2023Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
733000 usd
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1732000 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3154000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21600000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23100000 usd
CY2024Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
5591000 usd
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6466000 usd
CY2024Q3 clpt Inventory Software Licenses
InventorySoftwareLicenses
174000 usd
CY2023Q4 clpt Inventory Software Licenses
InventorySoftwareLicenses
211000 usd
CY2024Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1294000 usd
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1234000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
7059000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
7911000 usd
CY2024Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
198000 usd
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
386000 usd
CY2024Q3 clpt Inventory Net Including Noncurrent
InventoryNetIncludingNoncurrent
7257000 usd
CY2023Q4 clpt Inventory Net Including Noncurrent
InventoryNetIncludingNoncurrent
8297000 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
200000 usd
CY2024Q3 us-gaap Lease Cost
LeaseCost
200000 usd
us-gaap Lease Cost
LeaseCost
700000 usd
us-gaap Lease Cost
LeaseCost
500000 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1904000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1584000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5204000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4536000 usd
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1904000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1584000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5204000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4536000 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1478157 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.40
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
12000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.89
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
7237 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
42.19
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1458920 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.28
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y8M26D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8187000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1328249 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.19
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y4M24D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
7911000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1458920 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.28
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y8M26D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
8187000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
62800 shares
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001285550-24-000121-index-headers.html Edgar Link pending
0001285550-24-000121-index.html Edgar Link pending
0001285550-24-000121.txt Edgar Link pending
0001285550-24-000121-xbrl.zip Edgar Link pending
clpt-20240930.htm Edgar Link pending
clpt-20240930.xsd Edgar Link pending
clpt-20240930xex311.htm Edgar Link pending
clpt-20240930xex312.htm Edgar Link pending
clpt-20240930xex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
clpt-20240930_cal.xml Edgar Link unprocessable
clpt-20240930_def.xml Edgar Link unprocessable
clpt-20240930_lab.xml Edgar Link unprocessable
clpt-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
clpt-20240930_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending